Navigating SCAN Health Plan Xarelto Prior Authorization
Securing prior authorization for high-cost medications like Xarelto from SCAN Health Plan presents specific administrative challenges. This guide offers operational clarity for healthcare teams.
Managing prior authorization for specialty medications is a significant operational burden across health systems. When dealing with high-cost anticoagulants like Xarelto (rivaroxaban), especially with a payer like SCAN Health Plan, the administrative overhead can impact patient care timelines and revenue cycles. Understanding the specific requirements for SCAN Health Plan Xarelto prior authorization is critical for efficient approval rates and reduced claim denials. This guide provides direct, operator-level insights into navigating this particular payer-drug combination.
SCAN Health Plan's General Prior Authorization Framework for Pharmacy Benefits
SCAN Health Plan, like many Medicare Advantage and managed care organizations, employs a robust prior authorization program for prescription drugs. This program is designed to ensure medical necessity, optimize therapeutic outcomes, and manage pharmacy benefit costs. Medications listed on their formulary as requiring prior authorization are subject to specific clinical review before coverage is approved. This framework applies to both retail and specialty pharmacy benefits.
Xarelto (Rivaroxaban) Specific Prior Authorization Criteria
Xarelto, a direct oral anticoagulant (DOAC), is frequently prescribed for conditions such as non-valvular atrial fibrillation (NVAF), deep vein thrombosis (DVT) treatment and prevention, and pulmonary embolism (PE) treatment. SCAN Health Plan's prior authorization criteria for Xarelto typically align with FDA-approved indications and established clinical guidelines. Submitting teams must demonstrate that the patient meets specific diagnostic and treatment history criteria to justify the prescription. Documentation must clearly articulate the patient's current medical status and the rationale for choosing Xarelto over alternative therapies.
Key Documentation Required for Xarelto PA Submissions
Successful Xarelto prior authorization with SCAN Health Plan hinges on comprehensive and accurate documentation. Incomplete submissions are a primary cause of delays and denials. Clinical notes, diagnostic test results, and a clear treatment plan are essential. Teams should prepare to submit specific data points that directly address the payer's clinical criteria for rivaroxaban.
Essential Documentation Checklist for SCAN Health Plan Xarelto PA
- Patient demographics and insurance information, including SCAN Health Plan member ID.
- Prescriber's NPI and contact information.
- Diagnosis codes (ICD-10) supporting the medical necessity for Xarelto (e.g., I48.x for NVAF, I26.x for PE, I82.x for DVT).
- Relevant CPT codes if associated with a procedure or diagnostic workup.
- Detailed clinical notes from the prescribing physician, including patient history, physical exam findings, and current symptoms.
- Results of relevant diagnostic tests (e.g., echocardiogram, CT angiogram, D-dimer, INR if applicable to prior anticoagulant therapy).
- Documentation of prior anticoagulant therapy trials and failures or contraindications to alternative agents (e.g., warfarin).
- Current medication list, including dosages and frequency of Xarelto.
- Anticipated duration of Xarelto therapy.
Submission Methods and Communication Channels
SCAN Health Plan accepts prior authorization requests through several channels, including electronic prior authorization (ePA) platforms, their dedicated provider portal, fax, and telephone. Utilizing ePA via NCPDP SCRIPT standards or through established vendor integrations (e.g., CoverMyMeds, Surescripts) can often reduce turnaround times compared to manual methods. Direct communication with SCAN Health Plan's pharmacy benefit management (PBM) team is sometimes necessary for complex cases or appeals. Teams should identify the most efficient submission pathway compatible with their EMR (Epic Hyperspace, Cerner PowerChart) and internal workflows.
Understanding Denial Reasons and the Appeals Process
Denials for Xarelto prior authorization can stem from various issues, including insufficient clinical documentation, failure to meet specific step therapy requirements, or perceived lack of medical necessity based on SCAN's criteria. Upon denial, healthcare organizations have the right to appeal. The appeals process typically involves an initial reconsideration, followed by a formal appeal, and potentially an external review. Preparing for a peer-to-peer (P2P) discussion with a SCAN Health Plan medical director is a critical step in overturning denials. During a P2P, the prescribing clinician can provide additional context and clinical rationale directly to the payer's reviewer.
Impact on Revenue Cycle and Patient Care
Delays in Xarelto prior authorization directly affect the revenue cycle through increased administrative costs and potential claim denials. Furthermore, delays can postpone critical anticoagulant therapy, potentially leading to adverse patient outcomes. Proactive management of the PA process, including thorough documentation and timely submission, mitigates these risks. Implementing robust internal workflows and leveraging technology can reduce the administrative burden on prior authorization coordinators and improve overall efficiency. The goal is to minimize back-and-forth communication with the payer and secure approvals on the first submission.
Leveraging Technology for Efficient Prior Authorization Management
Modern prior authorization platforms integrate with EMRs and payer systems, automating data extraction and submission. Solutions that support X12 278 (HIPAA) transactions and Da Vinci PAS implementation can significantly improve throughput. These platforms can identify payer-specific requirements, flag missing documentation, and track authorization status in real-time. For Xarelto authorizations with SCAN Health Plan, such technology can help ensure adherence to specific clinical criteria and accelerate the approval process, freeing up staff for more complex cases.
Frequently asked questions
What are common reasons for Xarelto PA denial by SCAN Health Plan?
Common denial reasons include insufficient clinical documentation, failure to demonstrate medical necessity per SCAN's guidelines, lack of documented trial and failure of preferred alternatives (step therapy), or incomplete submission forms. Ensuring all required information, especially diagnosis codes and clinical history, is present and accurate is paramount.
How can we expedite the SCAN Health Plan Xarelto prior authorization process?
Expediting the process involves several steps: submitting all required documentation upfront, utilizing ePA platforms for electronic submission, and proactively tracking the status of submitted requests. Establishing direct communication channels with SCAN Health Plan's pharmacy services department for urgent cases can also be beneficial.
Does SCAN Health Plan accept ePA for Xarelto?
Yes, SCAN Health Plan generally accepts electronic prior authorization (ePA) submissions for medications like Xarelto. Utilizing ePA platforms that adhere to NCPDP SCRIPT standards or integrate directly with the payer's system can improve submission efficiency and often lead to faster review times compared to fax or phone submissions.
What is the appeals process for a denied Xarelto PA with SCAN Health Plan?
If a Xarelto PA is denied, the first step is typically a reconsideration request, often involving submission of additional clinical details. If still denied, a formal appeal can be filed. This process may include a peer-to-peer (P2P) discussion between the prescribing physician and a SCAN Health Plan medical reviewer to present further clinical justification.
Are there specific clinical criteria or guidelines SCAN Health Plan uses for Xarelto?
SCAN Health Plan's clinical criteria for Xarelto (rivaroxaban) are based on FDA-approved indications and may incorporate established evidence-based guidelines, such as those from ACC/AHA or other professional societies. These criteria typically specify required diagnoses, contraindications, and sometimes step therapy requirements or a history of intolerance to alternative anticoagulants.
Related coverage
Klivira automates prior authorization end-to-end.
See how it works for your EMR, payer mix, and specialty.